Compare T-Rex 2X Long MSTR Daily Target ETF (MSTU) vs Novavax Inc (NVAX) Price & Performance

MSTU, a US stock, trades at $33.31, down 8.64% in the last 24 hours. Technical indicators show a bullish trend with strong moving averages, while oscillators are neutral. The company recently executed a 10:1 reverse stock split and declared a $0.29 dividend for H2-2026. Key support and resistance levels are at $30 and $36, respectively.

The outlook for MSTU is mixed; bullish technicals contrast with negative media sentiment highlighting significant past value erosion. Risks include high volatility and leveraged ETF decay. Investors should weigh technical strength against fundamental uncertainties and sentiment concerns before considering a position.

Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.

The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.